These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32248243)

  • 1. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
    Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
    Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
    Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
    Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes.
    Turner MS; Isse K; Fischer DK; Turnquist HR; Morel PA
    Diabetologia; 2014 Jul; 57(7):1428-36. PubMed ID: 24737163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
    Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
    Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
    Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
    PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
    Axelsson S; Hjorth M; Ludvigsson J; Casas R
    Diabet Med; 2012 Oct; 29(10):1272-8. PubMed ID: 22587593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes.
    Ryden A; Stechova K; Durilova M; Faresjö M
    Diabetes Metab Res Rev; 2009 May; 25(4):335-43. PubMed ID: 19382103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GAD-alum immunotherapy in Type 1 diabetes mellitus.
    Morales AE; Thrailkill KM
    Immunotherapy; 2011 Mar; 3(3):323-32. PubMed ID: 21395375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
    Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
    Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
    Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
    Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
    Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
    J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.
    Tian J; Atkinson MA; Clare-Salzler M; Herschenfeld A; Forsthuber T; Lehmann PV; Kaufman DL
    J Exp Med; 1996 Apr; 183(4):1561-7. PubMed ID: 8666914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
    Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
    J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 T cells selected by antigen under Th2 polarizing conditions favor an elongated TCR alpha chain complementarity-determining region 3.
    Boyton RJ; Zaccai N; Jones EY; Altmann DM
    J Immunol; 2002 Feb; 168(3):1018-27. PubMed ID: 11801634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.
    Pichler R; Gruenbacher G; Culig Z; Brunner A; Fuchs D; Fritz J; Gander H; Rahm A; Thurnher M
    Cancer Immunol Immunother; 2017 Apr; 66(4):427-440. PubMed ID: 28005163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
    Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
    Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular differences between the divergent responses of ovalbumin-specific CD4 T cells to alum-precipitated ovalbumin compared to ovalbumin expressed by Salmonella.
    Serre K; Mohr E; Toellner KM; Cunningham AF; Granjeaud S; Bird R; MacLennan IC
    Mol Immunol; 2008 Aug; 45(13):3558-66. PubMed ID: 18582945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of paternal lymphocyte immunization on peripheral Th1/Th2 balance and TCR V beta and V gamma repertoire usage of patients with recurrent spontaneous abortions.
    Hayakawa S; Karasaki-Suzuki M; Itoh T; Ishii M; Kanaeda T; Nagai N; Takahashi-Yamamoto N; Tochigi M; Chishima F; Fujii TK; Oyama J; Kitanaka S; Satoh K
    Am J Reprod Immunol; 2000 Feb; 43(2):107-15. PubMed ID: 10735602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of Th1 or Th2 polarization of CD4+ T cell response induced by particulate antigen targeted to phagocytic cells.
    Sedlik C; Dériaud E; Leclerc C
    Int Immunol; 1997 Jan; 9(1):91-103. PubMed ID: 9043951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotransmitter signalling via NMDA receptors leads to decreased T helper type 1-like and enhanced T helper type 2-like immune balance in humans.
    Orihara K; Odemuyiwa SO; Stefura WP; Ilarraza R; HayGlass KT; Moqbel R
    Immunology; 2018 Mar; 153(3):368-379. PubMed ID: 28940416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.